Format

Send to

Choose Destination
J Mol Biol. 2018 Sep 14;430(18 Pt A):2900-2912. doi: 10.1016/j.jmb.2018.06.026. Epub 2018 Jun 20.

Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.

Author information

1
Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Cancer Cell Map Initiative, USA. Electronic address: jpshen@ucsd.edu.
2
Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Cancer Cell Map Initiative, USA.

Abstract

Synthetic lethal interactions, in which the simultaneous loss of function of two genes produces a lethal phenotype, are being explored as a means to therapeutically exploit cancer-specific vulnerabilities and expand the scope of precision oncology. Currently, three Food and Drug Administration-approved drugs work by targeting the synthetic lethal interaction between BRCA1/2 and PARP. This review examines additional efforts to discover networks of synthetic lethal interactions and discusses both challenges and opportunities regarding the translation of new synthetic lethal interactions into the clinic.

KEYWORDS:

cancer genomics; genetic interaction; precision medicine; synthetic lethal; systems biology

PMID:
29932943
PMCID:
PMC6097899
[Available on 2019-09-14]
DOI:
10.1016/j.jmb.2018.06.026

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center